- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04249258
Dobutamine on the Cardiac Conduction System
January 25, 2022 updated by: Northwell Health
The Effects of Dobutamine on the Cardiac Conduction System: Site-Specific Dose
Our hypothesis is that Dobutamine will act in a similar fashion to Isoproterenol with respect to cardiac conduction.
Our goal is to study the effects of Dobutamine on cardiac conduction and refractoriness during an Electrophysiology study (EPS).
At the end of most EPS Isoproterenol is commonly administered in an effort to change the conduction properties of the heart.
In our practice we have been using Dobutamine for this purpose for many years.
Dobutamine has never been rigorously studied for this indication however.
We designed this study to systematically study the effect of various doses of Dobutamine on the parameters of cardiac conduction and refractoriness that are commonly measured during an EPS.
We are specifically looking to compare the effect that Dobutamine has on the sinus node with the effect it has on the atrioventricular node.
Patients undergoing an EPS at Long Island Jewish Hospital will be recruited and consented.
Measurements of various conduction parameters will be taken at baseline as is standard protocol for an EPS.
Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min.
At each of these dosages the same conduction parameters will be measured.
A comparison will then be made between the conduction parameters at baseline and when the Dobutamine is administered.
Study Overview
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New Hyde Park, New York, United States, 11040
- Long Island Jewish Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, ages 18-80
- Patients must be diagnosed with a condition that necessitates an EPS. They must also be deemed to be in good enough medical health to be eligible to safely undergo an EPS. Medical eligibility will be determined by the Attending Electrophysiologist performing the EPS.
- For females of reproductive potential a negative pregnancy tes
Exclusion Criteria:
Patients with a resting left ventricular outflow gradient > 30mmHg
Patients with severe aortic stenosis
Patients with prior sustained ventricular tachycardia or ventricular fibrillation
Patients who are not able to consent for themselves
Patients with a prior allergic reaction to Dobutamine or any of its compounds including sulfites
Pregnant patients
Patients receiving B-blockers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Dobutamine
Measurements of various conduction parameters will be taken at baseline as is standard protocol for an EPS.
Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min.
At each of these dosages the same conduction parameters will be measured.
A comparison will then be made between the conduction parameters at baseline and when the Dobutamine is administered.
|
Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change in sinus cycle length and anterograde atrioventricular node Wenckebach cycle length with Dobutamine
Time Frame: The sinus cycle length and anterograde AV node Wenckebach cycle length will be measured from baseline and at the end of 5 minutes of each dobutamine dose of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min for a total of 20 minutes.
|
The difference between the change in the sinus cycle length from baseline to the highest dose of Dobutamine compared to the change in the anterograde AV node Wenckebach cycle length from baseline to the highest dose of Dobutamine.
|
The sinus cycle length and anterograde AV node Wenckebach cycle length will be measured from baseline and at the end of 5 minutes of each dobutamine dose of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min for a total of 20 minutes.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change in intervals measured in an EP study with Dobutamine
Time Frame: The parameters noted above will be measured at baseline and at the end of 5 minutes of each dose of dobutamine at 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min for a total of 20 minutes.
|
The relative changes in baseline of escalating doses of Dobutamine on the sinus cycle length (msec), AH interval (msec), HV interval (msec), QRS duration (msec), QTc (msec), AV node Wenckebach cycle length (msec), AV node effective refractory period (msec) and VA block cycle length (msec).
|
The parameters noted above will be measured at baseline and at the end of 5 minutes of each dose of dobutamine at 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min for a total of 20 minutes.
|
The change in blood pressure with Dobutamine
Time Frame: The blood pressure will be measured at baseline and at the end of 5 minutes of each dose of dobutamine at 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min for a total of 20 minutes.
|
The relative changes in baseline of escalating doses of Dobutamine on the blood pressure.
|
The blood pressure will be measured at baseline and at the end of 5 minutes of each dose of dobutamine at 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min for a total of 20 minutes.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bruce Goldner, MD, Northwell Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 14, 2020
Primary Completion (ACTUAL)
November 20, 2021
Study Completion (ACTUAL)
November 20, 2021
Study Registration Dates
First Submitted
January 21, 2020
First Submitted That Met QC Criteria
January 29, 2020
First Posted (ACTUAL)
January 30, 2020
Study Record Updates
Last Update Posted (ACTUAL)
January 26, 2022
Last Update Submitted That Met QC Criteria
January 25, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Adrenergic Agonists
- Cardiotonic Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Adrenergic beta-1 Receptor Agonists
- Dobutamine
Other Study ID Numbers
- 19-0934
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arrhythmias, Cardiac
-
Medtronic BRCCompletedAtrial Fibrillation | Risk of Cardiac ArrhythmiasNetherlands, Germany, Austria, Belgium, Canada, Czech Republic, Russian Federation, Slovakia
-
Ostfold University CollegeNot yet recruitingCardiac Arrest | Cardiac Arrhythmia | Cardiac Disease | Cardiac Death
-
Medical University of LodzRecruiting
-
Centro Cardiologico MonzinoMinistry of Health, ItalyRecruitingCardiac ArrhythmiaItaly
-
Ratika ParkashCardiac Arrhythmia Network of CanadaRecruiting
-
Boston Scientific CorporationRecruitingCardiac ArrythmiasUnited States, Monaco, Italy
-
EPD Solutions, A Philips CompanyPhilips HealthcareTerminatedCardiac ArrhythmiaUnited States
-
EPD Solutions, A Philips CompanyWithdrawn
-
Zoll Medical CorporationCompletedCardiac ArrhythmiaUnited States
-
Emory UniversityCompleted
Clinical Trials on Dobutamine
-
University of Sao PauloCompletedCoronary Disease | Cardiac Output, LowBrazil
-
University of Sao Paulo General HospitalUnknownHeart Failure | Cardiogenic Shock
-
Sichuan UniversityNot yet recruitingLaparoscopic HepatectomyChina
-
Medstar Health Research InstituteNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Heart Failure | Coronary Disease | Heart Failure, Congestive
-
University Hospital TuebingenFördergemeinschaft Deutsche Kinderherzzentren, Bonn, GermanyCompletedRight Ventricular DysfunctionGermany
-
University of AvignonCompletedDiabetes-related ComplicationsFrance
-
University Health Network, TorontoNot yet recruiting
-
Steen Hvitfeldt PoulsenRecruitingAortic Stenosis | Transthyretin Amyloid CardiomyopathyDenmark
-
Odense University HospitalUniversity of Southern Denmark; Region of Southern DenmarkRecruitingAortic Valve Stenosis | Valvular Heart Disease | Valvular StenosisDenmark
-
University Hospital, GhentCompletedGeneral AnesthesiaBelgium